Top

RACE-2: long-term follow-up of patients participating in RACE: the prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for Severe Aplastic Anemia patients

Type d'étude:

Non-interventional Prospective Studies

Numéro de l'étude:

84090088

Type de traitement à base de cellules souches:

Maladies:

Bone marrow failure

Titre court:

RACE-2: long-term follow-up

Objectif principal:

To evaluate the long-term outcome and survival of patients who have received standard IST with or without Eltrombopag within the RACE trial.

Principaux critères d'inclusion:

Subject participated in the RACE trial (EudraCT number: 2014-000363-40) during which patient received ATGAM, Cyclosporine A with or without Eltrombopag.

Pays:

Investigateur principal:

Régis Peffault de Latour, Antonio M. Risitano

Coordinateur EBMT de l'étude:

Brian Piepenbroek

E-mail du coordinateur de l'étude:

saawpebmt@lumc.nl